# William Camu

List of Publications by Year
in descending order



| 154 | 11,602 | 36271 | 30058 |
|---|---|---|---|
| papers | citations | 51 h-index | 103 g-index |

| 191 | 191 | 191 | 13427 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study. Neurology and Therapy, 2022, 11, 633-658. | 1.4 | 3 |
| 2 | Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients. CNS Neuroscience and Therapeutics, 2022, 28, 1532-1538. | 1.9 | 7 |
| 3 | Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 99, 102.e11-102.e20. | 1.5 | 20 |
| 4 | Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. Journal of Neuroradiology, 2021, 48, 170-175. | 0.6 | 4 |
| 5 | Effect of familial clustering in the genetic screening of 235 French ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 479-484. | 0.9 | 7 |
| 6 | Increased worsening of amyotrophic lateral sclerosis patients during Covid-19-related lockdown in France. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 505-507. | 1.1 | 12 |
| 7 | Editorial: Vitamin D in Neurological Diseases: From Pathophysiology to Therapy. Frontiers in Neurology, 2021, 12, 614900. | 1.1 | 4 |
| 8 | Impact of a frequent nearsplice SOD1 variant in amyotrophic lateral sclerosis: optimising SOD1 genetic screening for gene therapy opportunities. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 942-949. | 0.9 | 7 |
| 9 | Evidence of mosaicism in SPAST variant carriers in four French families. European Journal of Human Genetics, 2021, 29, 1158-1163. | 1.4 | 3 |
| 10 | High rate of hypomorphic variants as the cause of inherited ataxia and related diseases: study of a cohort of 366 families. Genetics in Medicine, 2021, 23, 2160-2170. | 1.1 | 13 |
| 11 | An amyotrophic lateral sclerosis hot spot in the French Alps associated with genotoxic fungi. Journal of the Neurological Sciences, 2021, 427, 117558. | 0.3 | 21 |
| 12 | Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236. | 4.5 | 46 |
| 13 | Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq1 1 0.784314 rgBT /Overloc<br>821-831. | 4.9 | 9 |
| 14 | Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Communications, 2021, 3, fcab141. | 1.5 | 17 |
| 15 | SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811. | 3.7 | 7 |
| 16 | Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. European Journal of Neurology, 2020, 27, 251-257. | 1.7 | 58 |
| 17 | Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. Revue Neurologique, 2020, 176, 100-112. | 0.6 | 11 |
| 18 | Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine, 2020, 59, 102844. | 2.7 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | ConnaÃ®tre la sclÃ©rose latÃ©rale amyotrophique pour mieux accompagner lesÂpatients. Actualites Pharmaceutiques, 2020, 59, 22-25. | 0.0 | 0 |
| 20 | Prise enÂcharge dâ€™uneÂpersonne atteinte deÂsclÃ©rose latÃ©rale amyotrophique. Actualites Pharmaceutiques, 2020, 59, 26-28. | 0.0 | 0 |
| 21 | Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort. Frontiers in Neuroscience, 2020, 14, 316. | 1.4 | 10 |
| 22 | Oligogenicity, C9orf72 expansion, and variant severity in ALS. Neurogenetics, 2020, 21, 227-242. | 0.7 | 13 |
| 23 | Low 25OH Vitamin D Blood Levels Are Independently Associated With Higher Amyotrophic Lateral Sclerosis Severity Scores: Results From a Prospective Study. Frontiers in Neurology, 2020, 11, 363. | 1.1 | 6 |
| 24 | High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study. EClinicalMedicine, 2020, 19, 100254. | 3.2 | 9 |
| 25 | Pre-symptomatic diagnosis in ALS. Revue Neurologique, 2020, 176, 166-169. | 0.6 | 8 |
| 26 | Autosomal dominant SPG9: intrafamilial variability and onset during pregnancy. Neurological Sciences, 2020, 41, 1931-1933. | 0.9 | 3 |
| 27 | Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?. International Journal of Molecular Sciences, 2019, 20, 3858. | 1.8 | 42 |
| 28 | An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs, 2019, 33, 1187-1199. | 2.7 | 59 |
| 29 | Theme 4 In vivo experimental models. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 160-187. | 1.1 | 1 |
| 30 | Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, . | 3.1 | 70 |
| 31 | ALS and environment: Clues from spatial clustering?. Revue Neurologique, 2019, 175, 652-663. | 0.6 | 21 |
| 32 | Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481. | 2.8 | 118 |
| 33 | Phenotypic and genotypic studies of ALS cases in ALS-SMA families. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 432-437. | 1.1 | 8 |
| 34 | Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273. | 6.3 | 684 |
| 35 | Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415. | 4.9 | 238 |
| 36 | Liver X Receptor Genes Variants Modulate ALS Phenotype. Molecular Neurobiology, 2018, 55, 1959-1965. | 1.9 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurology, The, 2018, 17, 689-698. | 4.9 | 48 |
| 38 | The Use of Peripherally Inserted Central Catheter in Amyotrophic Lateral Sclerosis Patients at a Later Stage. European Neurology, 2017, 77, 87-90. | 0.6 | 4 |
| 39 | Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216. | 4.9 | 62 |
| 40 | Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. Journal of Autoimmunity, 2017, 79, 84-90. | 3.0 | 67 |
| 41 | Adult-onset spinal muscular atrophy: An update. Revue Neurologique, 2017, 173, 308-319. | 0.6 | 17 |
| 42 | <scp>SOD</scp>1 mutation can mask C9<scp>orf</scp>72 abnormal expansion. European Journal of Neurology, 2017, 24, e24. | 1.7 | 2 |
| 43 | Slowly progressive motor neuron disease with multi-system involvement related to p.E121G SOD1 mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 296-297. | 1.1 | 1 |
| 44 | Teriflunomideâ€induced psoriasiform changes of fingernails: a new example of paradoxical side effect?. International Journal of Dermatology, 2017, 56, 1479-1481. | 0.5 | 10 |
| 45 | Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 519-527. | 1.1 | 17 |
| 46 | KCC3 loss-of-function contributes to Andermann syndrome by inducing activity-dependent neuromuscular junction defects. Neurobiology of Disease, 2017, 106, 35-48. | 2.1 | 8 |
| 47 | Liver X receptors: from cholesterol regulation to neuroprotectionâ€"a new barrier against neurodegeneration in amyotrophic lateral sclerosis?. Cellular and Molecular Life Sciences, 2016, 73, 3801-3808. | 2.4 | 11 |
| 48 | CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology, 2016, 87, 2491-2494. | 1.5 | 18 |
| 49 | The relationship between the rate of brain volume loss during first 24Âmonths and disability progression over 24 and 48Âmonths in relapsing MS. Journal of Neurology, 2016, 263, 299-305. | 1.8 | 10 |
| 50 | MACVIA-LR (FIGHTING CHRONIC DISEASES FOR ACTIVE AND HEALTHY AGEING IN LANGUEDOC-ROUSSILLON): A SUCCESS STORY OF THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING. Journal of Frailty & Aging,the, 2016, 5, 1-9. | 0.8 | 8 |
| 51 | Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1251-1261. | 1.4 | 131 |
| 52 | A common functional allele of the Nogo receptor gene, reticulon 4 receptor (RTN4R), is associated with sporadic amyotrophic lateral sclerosis in a French population. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 490-496. | 1.1 | 6 |
| 53 | Vitamin <scp>D</scp> is associated with degree of disability in patients with fully ambulatory relapsingâ€"remitting multiple sclerosis. European Journal of Neurology, 2015, 22, 564-569. | 1.7 | 47 |
| 54 | Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Human Molecular Genetics, 2015, 24, 1363-1373. | 1.4 | 122 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme. BMJ Open, 2014, 4, e005528-e005528. | 0.8 | 25 |
| 56 | A prospective observational postâ€marketing study of natalizumabâ€treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The <scp>BIONAT</scp> cohort. European Journal of Neurology, 2014, 21, 40-48. | 1.7 | 37 |
| 57 | Switching From Natalizumab to Fingolimod in Multiple Sclerosis. JAMA Neurology, 2014, 71, 436. | 4.5 | 133 |
| 58 | A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions inC9orf72reveals marked differences in results among 14 laboratories. Journal of Medical Genetics, 2014, 51, 419-424. | 1.5 | 118 |
| 59 | MACVIA-LR, Reference site of the European Innovation Partnership on Active and Healthy Ageing (EIP on) Tj ETQq1 1 0.784314 rgBT /Ov | 1.2 | 29 |
| 60 | Peripheral Myelin Protein 22 gene duplication with atypical presentations: A new example of the wide spectrum of Charcot-Marie-Tooth 1A disease. Neuromuscular Disorders, 2014, 24, 524-528. | 0.3 | 18 |
| 61 | Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiology of Aging, 2014, 35, 1198-1205. | 1.5 | 78 |
| 62 | Systems Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies. Current Pharmaceutical Design, 2014, 20, 5928-5944. | 0.9 | 63 |
| 63 | Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. Neurobiology of Aging, 2013, 34, 1311.e1-1311.e2. | 1.5 | 31 |
| 64 | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360. | 9.4 | 1,213 |
| 65 | C9ORF72 Repeat Expansions in the Frontotemporal Dementias Spectrum of Diseases: A Flow-chart for Genetic Testing. Journal of Alzheimer's Disease, 2013, 34, 485-499. | 1.2 | 93 |
| 66 | Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. European Journal of Human Genetics, 2013, 21, 237-239. | 1.4 | 29 |
| 67 | A Rare Motor Neuron Deleterious Missense Mutation in theDPYSL3(CRMP4) Gene is Associated with ALS. Human Mutation, 2013, 34, 953-960. | 1.1 | 30 |
| 68 | Investigating the contribution of VAPB/ALS8 loss of function in amyotrophic lateral sclerosis. Human Molecular Genetics, 2013, 22, 2350-2360. | 1.4 | 75 |
| 69 | Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 2013, 7, 214. | 1.8 | 39 |
| 70 | Dietary BMAA Exposure in an Amyotrophic Lateral Sclerosis Cluster from Southern France. PLoS ONE, 2013, 8, e83406. | 1.1 | 116 |
| 71 | C9orf72 Hexanucleotide Repeat Expansions as the Causative Mutation for Chromosome 9p21â€“Linked Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Archives of Neurology, 2012, 69, 1159-63. | 4.9 | 22 |
| 72 | Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology, 2012, 78, 1519-1526. | 1.5 | 72 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Ipsilateral Uveitis and Optic Neuritis in Multiple Sclerosis. Multiple Sclerosis International, 2012, 2012, 1-4. | 0.4 | 9 |
| 74 | Phenotype difference between ALS patients with expanded repeats inC9ORF72and patients with mutations in other ALS-related genes. Journal of Medical Genetics, 2012, 49, 258-263. | 1.5 | 157 |
| 75 | Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 839.e1-839.e3. | 1.5 | 34 |
| 76 | Analysis of the SORT1 gene in familial amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 1845.e7-1845.e9. | 1.5 | 2 |
| 77 | UBQLN2 mutations are rare in French and Frenchâ€“Canadian amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 2230.e1-2230.e5. | 1.5 | 40 |
| 78 | Amyotrophic lateral sclerosis: A hormonal condition?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 585-588. | 2.3 | 57 |
| 79 | Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology, 2012, 79, 2214-2216. | 1.5 | 56 |
| 80 | Study of the HFE gene common polymorphisms in French patients with sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2012, 317, 58-61. | 0.3 | 22 |
| 81 | Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. European Journal of Human Genetics, 2012, 20, 588-591. | 1.4 | 21 |
| 82 | Subcutaneous IFN-Î²1a to treat relapsingâ€“remitting multiple sclerosis. Expert Review of Neurotherapeutics, 2012, 12, 1283-1291. | 1.4 | 0 |
| 83 | Identification of a FUS splicing mutation in a large family with amyotrophic lateral sclerosis. Journal of Human Genetics, 2011, 56, 247-249. | 1.1 | 19 |
| 84 | Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2011, 303, 124-127. | 0.3 | 33 |
| 85 | Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 555.e13-555.e14. | 1.5 | 43 |
| 86 | Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 557.e11-557.e13. | 1.5 | 68 |
| 87 | APOE Îµ4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. European Journal of Neurology, 2011, 18, 1046-1052. | 1.7 | 17 |
| 88 | Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clinical Immunology, 2011, 138, 239-246. | 1.4 | 24 |
| 89 | Identification of novelFUSmutations in sporadic cases of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 113-117. | 2.3 | 28 |
| 90 | TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Human Molecular Genetics, 2011, 20, 1400-1410. | 1.4 | 323 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Respiratory onset in an ALS family with L144F SOD1 mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 747-749. | 0.9 | 6 |
| 92 | The P413L chromogranin B variation in French patients with sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 210-214. | 2.3 | 7 |
| 93 | Association of Long ATXN2 CAG Repeat Sizes With Increased Risk of Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 739-42. | 4.9 | 80 |
| 94 | Resequencing of 29 Candidate Genes in Patients With Familial and Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 587-93. | 4.9 | 52 |
| 95 | High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Multiple Sclerosis Journal, 2011, 17, 720-724. | 1.4 | 17 |
| 96 | Diabetes insipidus as a first manifestation in multiple sclerosis. Neurology, 2011, 76, 1939-1940. | 1.5 | 3 |
| 97 | Analysis of the UNC13A Gene as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2010, 67, 516-7. | 4.9 | 28 |
| 98 | A Major Determinant for Binding and Aminoacylation of tRNAAla in Cytoplasmic Alanyl-tRNA Synthetase Is Mutated in Dominant Axonal Charcot-Marie-Tooth Disease. American Journal of Human Genetics, 2010, 86, 77-82. | 2.6 | 194 |
| 99 | Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient Preference and Adherence, 2010, 4, 127. | 0.8 | 4 |
| 100 | Neuromyelitis optica in France. Neurology, 2010, 74, 736-742. | 1.5 | 196 |
| 101 | SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. Journal of Medical Genetics, 2010, 47, 554-560. | 1.5 | 266 |
| 102 | Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 572-577. | 0.9 | 57 |
| 103 | Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology, 2010, 75, 1084-1088. | 1.5 | 101 |
| 104 | Questioning on the role of D amino acid oxidase in familial amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, E107; author reply E108. | 3.3 | 19 |
| 105 | FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. Journal of Alzheimer's Disease, 2010, 22, 765-9. | 1.2 | 75 |
| 106 | Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21777-21782. | 3.3 | 49 |
| 107 | Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology, 2009, 73, 1176-1179. | 1.5 | 129 |
| 108 | High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 113-117. | 2.3 | 135 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology, 2009, 72, 1669-1676. | 1.5 | 90 |
| 110 | TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Annals of Neurology, 2009, 65, 470-473. | 2.8 | 278 |
| 111 | Cutaneous adverse events related to glatiramer acetate injection (copolymerâ€1,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 667 Td 2009, 23, 1332-1333. | 1.3 | 12 |
| 112 | A Mutation that Creates a Pseudoexon in SOD1 Causes Familial ALS. Annals of Human Genetics, 2009, 73, 652-657. | 0.3 | 32 |
| 113 | Association study of the ubiquitin conjugating enzyme gene UBE2H in sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 432-435. | 2.3 | 9 |
| 114 | The importance of theSMNgenes in the genetics of sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 436-440. | 2.3 | 30 |
| 115 | NOMADâ€™ MUS : crÃ©ation dâ€™une cohorte franÃ§aise de neuro-optico-myÃ©lite aiguÃ« de Devic et des syndromes neurologiques apparentÃ©s. Revue Neurologique, 2009, 165, S57-S58. | 0.6 | 0 |
| 116 | NeuromyÃ©lite optique de Devic et patients Ã haut risquÃ© : enquÃªte rÃ©trospective nationale. Revue Neurologique, 2009, 165, S55-S56. | 0.6 | 0 |
| 117 | TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genetics, 2008, 40, 572-574. | 9.4 | 1,371 |
| 118 | Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. European Journal of Neurology, 2008, 15, 1245-1251. | 1.7 | 135 |
| 119 | Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. Journal of Medical Genetics, 2008, 46, 112-114. | 1.5 | 162 |
| 120 | Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology, 2008, 71, 514-520. | 1.5 | 51 |
| 121 | Mutations of the ANG Gene in French Patients With Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 1333. | 4.9 | 52 |
| 122 | Three Families With Amyotrophic Lateral Sclerosis and Frontotemporal Dementia With Evidence of Linkage to Chromosome 9p. Archives of Neurology, 2007, 64, 240. | 4.9 | 111 |
| 123 | Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 941-944. | 1.4 | 16 |
| 124 | SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. Neurology, 2006, 67, 1147-1150. | 1.5 | 80 |
| 125 | A Frameshift Deletion in Peripherin Gene Associated with Amyotrophic Lateral Sclerosis. Journal of Biological Chemistry, 2004, 279, 45951-45956. | 1.6 | 163 |
| 126 | Absence of mutations in the hypoxia response element ofVEGF in ALS. Muscle and Nerve, 2003, 28, 774-775. | 1.0 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | N19S, a new SOD1 mutation in sporadic amyotrophic lateral sclerosis: No evidence for disease causation. Annals of Neurology, 2003, 53, 815-818. | 2.8 | 23 |
| 128 | A Clustering of Conjugal Amyotrophic Lateral Sclerosis in Southeastern France. Archives of Neurology, 2003, 60, 553. | 4.9 | 40 |
| 129 | Mutation Screening of the ALS2 Gene in Sporadic and Familial Amyotrophic Lateral Sclerosis. Archives of Neurology, 2003, 60, 1768. | 4.9 | 40 |
| 130 | SMN1 gene study in three families in which ALS and spinal muscular atrophy co-exist. Neurology, 2002, 59, 1464-1466. | 1.5 | 14 |
| 131 | A Novel Locus for Familial Amyotrophic Lateral Sclerosis, on Chromosome 18q. American Journal of Human Genetics, 2002, 70, 251-256. | 2.6 | 131 |
| 132 | Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Annals of Neurology, 2002, 51, 243-246. | 2.8 | 111 |
| 133 | Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. Annals of Neurology, 2001, 49, 267-271. | 2.8 | 80 |
| 134 | Motor neuron disease after electric injury. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 265-267. | 0.9 | 46 |
| 135 | Letter to the editor. Muscle and Nerve, 2000, 23, 1610-1611. | 1.0 | 13 |
| 136 | Coexistence of dominant and recessive familial amyotrophic lateral sclerosis with the D90A Cu,Zn superoxide dismutase mutation within the same country. European Journal of Neurology, 2000, 7, 207-211. | 1.7 | 37 |
| 137 | Bullous Pemphigoid and Amyotrophic Lateral Sclerosis. Archives of Dermatology, 2000, 136, 521-4. | 1.7 | 47 |
| 138 | Acute hepatitis after riluzole administration. Journal of Hepatology, 1999, 30, 527-530. | 1.8 | 41 |
| 139 | Genetics of familial ALS and consequences for diagnosis. Journal of the Neurological Sciences, 1999, 165, S21-S26. | 0.3 | 74 |
| 140 | Association between centromeric deletions of theSMN gene and sporadic adult-onset lower motor neuron disease. Annals of Neurology, 1998, 43, 640-644. | 2.8 | 75 |
| 141 | Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Human Molecular Genetics, 1998, 7, 2045-2050. | 1.4 | 132 |
| 142 | Hydrogen peroxide-induced motoneuron apoptosis is prevented by poly ADP ribosyl synthetase inhibitors. NeuroReport, 1998, 9, 1835-1838. | 0.6 | 34 |
| 143 | Identification of Six Novel SOD1 Gene Mutations in Familial Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences, 1998, 25, 192-196. | 0.3 | 75 |
| 144 | Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. Journal of the Neurological Sciences, 1996, 139, 34-37. | 0.3 | 84 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Motor evoked potentials (MEPs): evaluation of the different types of responses in amyotrophic lateral sclerosis and primary lateral sclerosis. Electromyography and Clinical Neurophysiology, 1996, 36, 361-8. | 0.2 | 21 |
| 146 | Survival of newly postmitotic motoneurons is transiently independent of exogenous trophic support. Journal of Neuroscience, 1995, 15, 3128-3137. | 1.7 | 29 |
| 147 | Embryonic rat motoneurons express a functional P-type voltage-dependent calcium channel. International Journal of Developmental Neuroscience, 1995, 13, 429-436. | 0.7 | 22 |
| 148 | Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature, 1993, 363, 266-270. | 13.7 | 605 |
| 149 | Purification of Spinal Motoneurons from Chicken and Rat Embryos by Immunopanning. Methods, 1993, 2, 191-199. | 0.5 | 12 |
| 150 | Motoneuron survival factors: Biological roles and therapeutic potential. Neuromuscular Disorders, 1993, 3, 455-458. | 0.3 | 23 |
| 151 | Neurotrophic factors in development and plasticity of spinal neurons. Restorative Neurology and Neuroscience, 1993, 5, 15-28. | 0.4 | 16 |
| 152 | Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurologica Scandinavica, 1993, 88, 51-55. | 1.0 | 71 |
| 153 | Coexistence of amyotrophic lateral sclerosis and Werdnig-Hoffmann disease within a family. Muscle and Nerve, 1993, 16, 569-70. | 1.0 | 10 |
| 154 | Purification of embryonic rat motoneurons by panning on a monoclonal antibody to the low-affinity NGF receptor. Journal of Neuroscience Methods, 1992, 44, 59-70. | 1.3 | 153 |